Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$351 Mln
P/E Ratio
--
P/B Ratio
1.96
Industry P/E
--
Debt to Equity
0.06
ROE
-0.58 %
ROCE
-54.07 %
Div. Yield
0 %
Book Value
1.63
EPS
-0.94
CFO
$-223.57 Mln
EBITDA
$-289.22 Mln
Net Profit
$-337.80 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Absci Corp (ABSI)
| 11.83 | -2.98 | -40.33 | -40.33 | -5.66 | -- | -- |
|
BSE Sensex*
| 5.11 | 9.44 | 7.98 | 13.19 | 15.83 | 21.26 | 11.83 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Absci Corp (ABSI)
| -37.38 | 100.00 | -74.39 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 53.40 | 9,739.38 | -- | -36.37 | |
| 36.98 | 9,967.87 | 20.55 | 23.13 | |
| 25.70 | 9,378.49 | -- | -30.53 | |
| 120.43 | 11,451.33 | 39.09 | 11.64 |
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its preclinical... development programs include ABS-101 for the treatment of inflammatory bowel disease; ABS-201 for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, and Owkin for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington. Read more
Founder, CEO, President & Director
Mr. Sean McClain
Founder, CEO, President & Director
Mr. Sean McClain
Headquarters
Vancouver, WA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Absci Corp (ABSI) stood at $ 214 Mln as on 31-Dec-24
The share price of Absci Corp (ABSI) is $2.93 (NASDAQ) as of 12-May-2025 16:26 EDT. Absci Corp (ABSI) has given a return of -5.66% in the last 3 years.
Absci Corp (ABSI) has a market capitalisation of $ 351 Mln as on 09-May-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Absci Corp (ABSI) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Absci Corp (ABSI) and enter the required number of quantities and click on buy to purchase the shares of Absci Corp (ABSI).
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its preclinical development programs include ABS-101 for the treatment of inflammatory bowel disease; ABS-201 for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, and Owkin for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
The CEO & director of Mr. Sean McClain. is Absci Corp (ABSI), and CFO & Sr. VP is Mr. Sean McClain.
There is no promoter pledging in Absci Corp (ABSI).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,098
|
|
|
1,086
|
|
|
1,077
|
|
|
1,006
|
| Absci Corp (ABSI) | Ratios |
|---|---|
|
Return on equity(%)
|
-58.04
|
|
Operating margin(%)
|
-2260.06
|
|
Net Margin(%)
|
-2274.06
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Absci Corp (ABSI) was $0 Mln.
$0.18
(
